tqb2868
mAbexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Apr 27, 2022 (NCT05198505)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07165951 | Phase 3 | Nov 30, 2025 | Government of China |
| NCT06441019 | Phase 2 | Jul 1, 2024 | Fudan University |
| NCT06767813 | Phase 2 | Mar 19, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT05998941 | Phase 2 | Aug 31, 2023 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT05198505 | Phase 1 | Apr 27, 2022 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 3 | 3 | 2 | 2022 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Government of China | Government | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1